A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Type 2 diabetes results when the body does not produce enough insulin to regulate blood sugar. This study is designed to measure the effect of vildagliptin on the maximum insulin secretion by the pancreas.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
30 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Diagnosed with type 2 diabetes for at least 6 months
Patients whose diabetes is controlled by diet and exercise only or patients taking metformin
BMI in the range 22-45
Blood glucose criteria must be met
Pregnancy or lactation
Type 1 diabetes or diabetes resulting from pancreatic injury
Cardiovascular complications as defined by the protocol
Significant diabetic complications as defined by the protocol
Other protocol-defined inclusion/exclusion criteria may apply